Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer

被引：128

作者：

Gaynor, Nicola ^{[1
]}

Crown, John ^{[1
,2
]}

Collins, Denis M. ^{[1
]}

机构：

[1] Dublin City Univ, Natl Inst Cellular Biotechnol, Dublin 9, Ireland

[2] St Vincents Univ Hosp, Dept Med Oncol, Elm Pk, Dublin 4, Ireland

来源：

SEMINARS IN CANCER BIOLOGY | 2022年 / 79卷

关键词：

Clinical studies; PD-1; PD-L1; CTLA-4; Breast cancer; CELL LUNG-CANCER; METASTATIC UROTHELIAL CARCINOMA; TUMOR-INFILTRATING LYMPHOCYTES; SINGLE-ARM; FDA APPROVAL; DOUBLE-BLIND; OPEN-LABEL; MALIGNANT MESOTHELIOMA; MOLECULAR PORTRAITS; ANTI-PD-L1; ANTIBODY;

D O I：

10.1016/j.semcancer.2020.06.016

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This review focuses on immune checkpoint inhibitors - immunomodulatory agents that aim to relieve tumourmediated immune-cell suppression. Immune checkpoint proteins can be expressed on the tumour-cell or immune-cell populations. Immune checkpoint proteins dampen the immune response by inactivating immune cells capable of tumour destruction. Blockade of immune checkpoints has shown impressive results in a range of solid cancers, particularly melanoma and non-small cell lung cancer. The potential benefit of this class of drugs is widespread across most cancer types and an unprecedented number of clinical studies are underway to examine the benefit of these agents. The aims of this review are to: provide an overview of the key early immune checkpoint inhibitor trials involving drugs targeting programmed cell death-1 (PD-1), programmed cell death ligand-1 (PD-L1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) in multiple disease types; provide an overview of emerging therapies aimed at these targets; and provide a detailed exploration of the status of immune checkpoint inhibitors in breast cancer.

引用

页码：44 / 57

页数：14

共 178 条

[1]

Adams S, 2019, ANN ONCOL, V30, P405, DOI [10.1093/annonc/mdy518, 10.1093/annonc/mdy517]

[2] Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199 [J].

Adams, Sylvia ;

Gray, Robert J. ;

Demaria, Sandra ;

Goldstein, Lori ;

Perez, Edith A. ;

Shulman, Lawrence N. ;

Martino, Silvana ;

Wang, Molin ;

Jones, Vicky E. ;

Saphner, Thomas J. ;

Wolff, Antonio C. ;

Wood, William C. ;

Davidson, Nancy E. ;

Sledge, George W. ;

Sparano, Joseph A. ;

Badve, Sunil S. .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) :2959-+

[3] Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors [J].

Akbay, Esra A. ;

Koyama, Shohei ;

Carretero, Julian ;

Altabef, Abigail ;

Tchaicha, Jeremy H. ;

Christensen, Camilla L. ;

Mikse, Oliver R. ;

Cherniack, Andrew D. ;

Beauchamp, Ellen M. ;

Pugh, Trevor J. ;

Wilkerson, Matthew D. ;

Fecci, Peter E. ;

Butaney, Mohit ;

Reibel, Jacob B. ;

Soucheray, Margaret ;

Cohoon, Travis J. ;

Janne, Pasi A. ;

Meyerson, Matthew ;

Hayes, D. Neil ;

Shapiro, Geoffrey I. ;

Shimamura, Takeshi ;

Sholl, Lynette M. ;

Rodig, Scott J. ;

Freeman, Gordon J. ;

Hammerman, Peter S. ;

Dranoff, Glenn ;

Wong, Kwok-Kin .

CANCER DISCOVERY, 2013, 3 (12) :1355-1363

[4] First FDA Approval of Neoadjuvant Therapy for Breast Cancer: Pertuzumab for the Treatment of Patients with HER2-Positive Breast Cancer [J].

Amiri-Kordestani, Laleh ;

Wedam, Suparna ;

Zhang, Lijun ;

Tang, Shenghui ;

Tilley, Amy ;

Ibrahim, Amna ;

Justice, Robert ;

Pazdur, Richard ;

Cortazar, Patricia .

CLINICAL CANCER RESEARCH, 2014, 20 (21) :5359-5364

[5] FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer [J].

Amiri-Kordestani, Laleh ;

Blumenthal, Gideon M. ;

Xu, Qiang Casey ;

Zhang, Lijun ;

Tang, Shenghui W. ;

Ha, Linan ;

Weinberg, Wendy C. ;

Chi, Bo ;

Candau-Chacon, Reyes ;

Hughes, Patricia ;

Russell, Anne M. ;

Miksinski, Sarah Pope ;

Chen, Xiao Hong ;

McGuinn, W. David ;

Palmby, Todd ;

Schrieber, Sarah J. ;

Liu, Qi ;

Wang, Jian ;

Song, Pengfei ;

Mehrotra, Nitin ;

Skarupa, Lisa ;

Clouse, Kathleen ;

Al-Hakim, Ali ;

Sridhara, Rajeshwari ;

Ibrahim, Amna ;

Justice, Robert ;

Pazdur, Richard ;

Cortazar, Patricia .

CLINICAL CANCER RESEARCH, 2014, 20 (17) :4436-4441

[6] Maturation and activation of dendritic cells induced by lymphocyte activation gene-3 (CD223) [J].

Andreae, S ;

Piras, F ;

Burdin, N ;

Triebel, F .

JOURNAL OF IMMUNOLOGY, 2002, 168 (08) :3874-3880

[7]

[Anonymous], 2018, Cancer Discov, V8, pOF2, DOI 10.1158/2159-8290.CD-NB2018-140

[8]

[Anonymous], 2017, Cancer Discov, V7, pOF1, DOI 10.1158/2159-8290.CD-NB2017-110

[9] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Yokoi, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

de Castro Carpeno, J. ;

Wadsworth, C. ;

Melillo, G. ;

Jiang, H. ;

Huang, Y. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) :1919-1929

[10]

Antonia S.J., 2016, J CLIN ONCOL, V34, P100

← 1 2 3 4 5 6 7 8 9 10 →